Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04029766
Other study ID # HSK3486Australia-03
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date November 10, 2015
Est. completion date June 9, 2016

Study information

Verified date June 2019
Source Haisco Pharmaceutical Group Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study was a single center, open-label, single dose escalation study in healthy male subjects to investigate a bolus dose followed by a 30 minute constant infusion of HSK3486 over two cohorts.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date June 9, 2016
Est. primary completion date December 14, 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 49 Years
Eligibility Inclusion Criteria: - 1. Male, aged 18 - 49 years (inclusive); - 2. Be in general good health without clinically significant medical history; - 3. American Society of Anesthesiologists (ASA) Physical Status Classification of I or II; - 4. Body Mass Index (BMI) between 18 and 30 kg/m2 (inclusive); - 5. Negative screen for drugs of abuse, alcohol, hepatitis B surface antigen (HBs-Ag), hepatitis C (HCVAb) and Human Immunodeficiency Virus (HIV) at Screening; and drugs of abuse, alcohol pre dose on Day -1 - 6. Normal or non-clinically significant findings on a physical examination, 12-lead electrocardiogram (ECG) and vital signs (respiration rate between 12 and 20 breaths per minute, blood pressure (BP) between 100-140/60-90 mmHg, heart rate between 50-99 beats per minute, temperature between 35.8°C and 37.5°C and pulse oximetry values > 95% on room air.); - 7. Clinical laboratory values within the normal limits as defined by the clinical laboratory, unless the Investigator decided that out-of-range values were not clinically significant; - 8. Ability to provide written informed consent; - 9. Willing and able to follow study instructions and likely to complete all study requirements; - 10. Suitable venous and arterial access. Exclusion Criteria: - 1. History of allergy or sensitivity to: propofol, components of Fresofol 1% MCT/LCT propofol, or HSK3486 (excipients soy bean oil, glycerine, triglycerides, purified egg phospholipids, sodium oleate and sodium hydroxide), or plain lignocaine; - 2. History of clinically significant problems with general anesthesia; - 3. Current smoker, or a history of regular (more than weekly) use of tobacco- or nicotine-containing products within 2 months prior to Screening; - 4. History of excessive alcohol intake (more than four standard drinks daily, on average) or use of recreational drugs within the last 3 months; - 5. Use of prescription or over the counter medications within 7 days of Investigational Product administration, with the exception of contraceptive medications, paracetamol, oral non-steroidal antiinflammatory agents, topical over the counter preparations and routine vitamins (if they do not exceed an intake of 20 to 600 times the recommended daily dose), unless agreed as non-clinically relevant by the Principal Investigator and Sponsor; - 6. Standard donation of blood within 30 days of the study; - 7. Donation of plasma or participation in a plasmapheresis program within 7 days preceding this study; - 8. Receipt of any investigational study drug within 30 days prior to Screening; - 9. Unable to fast for the 6 hours prior to Investigational Product administration; - 10. Clinically significant (as judged by the Investigator) presence of acute illness (e.g. gastrointestinal illness, infection such as influenza, upper respiratory tract infection) at admission to the clinical study unit; - 11. Anticipated need for surgery or hospitalization during the study; - 12. Anatomical abnormality that would potentially interfere with airway management under unconscious sedation or anesthesia; - 13. History of posture-related gastric reflux more than twice weekly; - 14. History of seizures or epilepsy ; - 15. History of ischaemic heart disease; - 16. History of brady- or tachy-dysrhythmias requiring medical care; - 17. History of asthma, with bronchospasm requiring treatment in the last 3 months; - 18. Any condition, which in the Investigator's opinion, put the subject at significant risk, could confound the study results or may interfere significantly with the subject's participation in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
HSK3486


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Sichuan Haisco Pharmaceutical Group Co., Ltd

Outcome

Type Measure Description Time frame Safety issue
Primary Safety by measurement of Adverse Events First dose of study drug on day 1
Secondary Modified observer's assessment of alertness/sedation(MOAA/S) Observe the change of modified observer's assessment of alert /sedation during the whole trial From first dose of study drug until fully alert on day 1
Secondary Bispectral index (BIS) From first dose of study drug until fully alert on day 1
Secondary Median effective dose (ED50) From first dose of study drug until fully alert on day 1
Secondary Peak concentration (Cmax) From the start of administration to 48 hours after administration
Secondary Time to plasma peak concentration(Tmax) From the start of administration to 48 hours after administration
Secondary Terminal elimination half life (t1/2z) and mean residence time (MRT) From the start of administration to 48 hours after administration
Secondary Mean residence time (MRT) From the start of administration to 48 hours after administration
Secondary Area Under the Curve (AUC0-30min, AUC0-1h, AUC0-last, and AUC0-inf) From the start of administration to 48 hours after administration
Secondary Total clearance (CL) From the start of administration to 48 hours after administration
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04580030 - Tricuapid Annular Plane Sistolic Excursion Before General Anesthesia Can Predict Hypotension After Induction
Active, not recruiting NCT04279054 - Decreased Neuraxial Morphine After Cesarean Delivery Early Phase 1
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Recruiting NCT04099693 - A Prospective Randomized Study of General Anesthesia Versus Anesthetist Administered Sedation for ERCP
Terminated NCT02481999 - Pre- and Postoperative EEG-Monitoring for Children Aged From 0,5 to 8 Years
Completed NCT04235894 - An Observer Rating Scale of Facial Expression Can Predict Dreaming in Propofol Anesthesia
Recruiting NCT05525104 - The Effect of DSA on Recovery of Anaesthesia in Children (Het Effect Van DSA op Het Herstel na Anesthesie Bij Kinderen). N/A
Recruiting NCT05024084 - Desflurane and Sevoflurane Minimal Flow Anesthesia on Recovery and Anesthetic Depth Phase 4
Completed NCT04204785 - Noise in the OR at Induction: Patient and Anesthesiologists Perceptions N/A
Completed NCT03277872 - NoL, HR and MABP Responses to Tracheal Intubation Performed With MAC Blade Versus Glidescope N/A
Terminated NCT03940651 - Cardiac and Renal Biomarkers in Arthroplasty Surgery Phase 4
Terminated NCT02529696 - Measuring Sedation in the Intensive Care Unit Using Wireless Accelerometers
Completed NCT05346588 - THRIVE Feasibility Trial Phase 3
Terminated NCT03704285 - Development of pk/pd Model of Propofol in Patients With Severe Burns
Recruiting NCT05259787 - EP Intravenous Anesthesia in Hysteroscopy Phase 4
Completed NCT02894996 - Does the Response to a Mini-fluid Challenge of 3ml/kg in 2 Minutes Predict Fluid Responsiveness for Pediatric Patient? N/A
Completed NCT05386082 - Anesthesia Core Quality Metrics Consensus Delphi Study
Terminated NCT03567928 - Laryngeal Mask in Upper Gastrointestinal Procedures N/A
Recruiting NCT06074471 - Motor Sparing Supraclavicular Block N/A
Completed NCT04163848 - CARbon Impact of aNesthesic Gas